4.8 Article

Amplification-free Detection of Cytomegalovirus miRNA Using a Modification-free Surface Plasmon Resonance Biosensor

期刊

ANALYTICAL CHEMISTRY
卷 93, 期 22, 页码 8002-8009

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.analchem.1c01093

关键词

-

资金

  1. Ministry of Education of Taiwan
  2. Ministry of Science and Technology [106-2113-M-002-014-MY3, 106-2622-M-002-003-CC2, 107-2622-M-002-001CC2, MOST-106 -2811-M-002-099, MOST 108-2112-M-034-001-MY3]

向作者/读者索取更多资源

A newly designed SPR biosensor was developed for CMV-specific microRNA detection, featuring a simple modification-free approach with high affinity, along with the use of magnetic nanoparticles for analyte separation and signal amplification. The sensor was successful in multidetection of CMV-related microRNAs and has potential for clinical diagnosis of CMV-specific microRNAs.
Cytomegalovirus (CMV) is the most frequent cause of congenital infection worldwide; congenital CMV may lead to significant mortality, morbidity, or long-term sequelae, such as sensorineural hearing loss. The current study presents a newly designed surface plasmon resonance (SPR) biosensor for CMV-specific microRNAs that does not involve extra care for receptor immobilization or treatment to prevent fouling on bare gold surfaces. The modification-free approach, which utilizes a poly-adenine [poly(A)]-Au interaction, exhibited a high affinity that was comparable to that of the gold-sulfur (Au-S) interaction. In addition, magnetic nanoparticles (MNPs) were used to separate the analyte from complex sample matrixes that significantly reduced nonspecific adsorption. Moreover, the MNPs also played an important role in SPR signal amplification due to the binding-induced change in the refractive index. Our SPR biosensing platform was used successfully for the multidetection of the microRNAs, UL22A-5p, and UL112-3p, which were associated with CMV. Our SPR biosensor offered the detection limits of 108 fM and 24 fM for UL22A-Sp and UL112-3p, respectively, with an R-2 of 0.9661 and 0.9985, respectively. The precision of this biosensor has an acceptable CV (coefficient of variation) value of <10%. In addition, our sensor is capable of discriminating between serum samples collected from healthy and CMV-infected newborns. Taken together, we believe that our newly developed SPR biosensing platform is a promising alternative for the diagnosis of CMV-specific microRNA in clinical settings, and its application for the detection of other miRNAs may be extended further.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据